Search clinical trials for: [11C]MK-6884

Total 3888 results

Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) (HYPERION)

Pulmonary Arterial Hypertension

United States, Belgium, France, Germany, Spain, Argentina, Australia, Austria, Colombia, Croatia, Denmark, Greece, Israel, Korea, Republic of, Netherlands, Portugal, Serbia, Taiwan, Brazil, Canada, Czechia, Italy, New Zealand, Sweden, S... and more
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Active, not recruiting

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (ZENITH)

Pulmonary Arterial Hypertension

France, Germany, United States, Australia, Belgium, Canada, Israel, Italy, Mexico, Netherlands, Spain, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

Chronic Heart Failure With Reduced Ejection Fraction

China, United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, New Zealand, Peru and more
Afferent Pharmaceuticals, Inc.

Completed

A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

Cough | Idiopathic Pulmonary Fibrosis
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
Reata, a wholly owned subsidiary of Biogen

Completed

A Human AME Study for Omaveloxolone

Healthy Male Subjects

United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Completed

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

HCV Infection

United States, Germany, Poland, Sweden
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Colorectal Neoplasms

United States, Canada
Merck Sharp & Dohme LLC

Completed

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Advanced/Metastatic Solid Tumors

United States, Canada
Merck Sharp & Dohme LLC

Terminated

A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

Type 2 Diabetes
Organon and Co

Completed

A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)

Hypertension
Hillier, Sharon, PhD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048 (FAME103)

Pharmacokinetics | Safety

United States
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Healthy Participants

Netherlands
Indivior Inc.

Completed

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Opioid Use Disorder

United States
Biogen
Denali Therapeutics Inc.

Completed

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)

Systolic Dysfunction
VelosBio Inc., a subsidiary of Merck & Co., Inc...

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Follicular Lymphoma | Acute Myeloid Leukemia | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Acute Lymphoid Leukemia | Richter Transformation Lymphoma | Lymphoplasmacytoid Lymphoma | T-cell Non-Hodgkin...

United States
Merck Sharp & Dohme LLC
Bayer; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)

Heart Failure | Chronic Heart Failure With Reduced Ejection Fraction
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Psoriasis
Merck Sharp & Dohme LLC

Completed

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Rosacea
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

Plaque Psoriasis
University of Texas Southwestern Medical Center
National Cancer Institute (NCI); Howard Hughes Medical Institute

Recruiting

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Kidney Cancer | Renal Cell Carcinoma | Urothelial Carcinoma | Hereditary Leiomyomatosis and Renal Cell Cancer | Metastatic Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | HLRCC | Clear Cell Carcinoma | Metastatic Kidney Cancer | Fumarate Hydratase Deficiency | Succinate...

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Burkitt Lymphoma | Ewing Sarcoma | Neuroblastoma | Diffuse Large B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC

Recruiting

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Hepatic Impairment | Non-alcoholic Steatohepatitis

United States
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

Renal Impairment

United States
Afferent Pharmaceuticals, Inc.

Completed

Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)

Refractory Chronic Cough

United Kingdom
Afferent Pharmaceuticals, Inc.

Completed

A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) (EPICC)

Chronic Cough
Merck Sharp & Dohme LLC

Completed

Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)

Chronic Cough

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Small Cell Lung Carcinoma

Poland, Russian Federation, United States, Australia, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Carcinoma, Renal Cell

United States, Colombia, Canada, Australia, Finland, Japan, United Kingdom, Brazil, Chile, China, Croatia, Czechia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Malaysia, Mexico, Norway, Philippines, Polan... and more
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Neoplasm

United States, Canada, Israel
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Neoplasm Metastasis
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Tammie L. S. Benzinger, MD, PhD

Recruiting

Imaging Biomarkers in Preclinical and Symptomatic AD (ACS_PIB_IND)

Alzheimer Disease

United States
Henrik Wiggers

Completed

Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography

Heart Failure, Systolic

Denmark
Turku University Hospital

Completed

PET/MRI and Biomarkers in Bladder Cancer (ACEBIB)

Bladder Cancer

Finland
Aarhus University Hospital

Completed

Metformin in Breast Cancer, Visualized With Positron Emission Tomography

Breast Cancer

Denmark
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Carcinoma, Renal Cell

China
Biogen
Denali Therapeutics Inc.

Completed

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Healthy Volunteers

United States
Loma Linda University

Terminated

Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy.

Traumatic Brain Injury
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
PegBio Co., Ltd.
Tigermed Consulting Co., Ltd

Completed

Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

Type 2 Diabetes Mellitus

China
Dow Pharmaceutical Sciences

Unknown

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 (IDP-118)

Plaque Psoriasis

United States
Brigham and Women's Hospital
Massachusetts General Hospital

Recruiting

Feasibility of [11C]Acetate-PET in LAM and TSC

Tuberous Sclerosis Complex | Lymphangioleiomyomatosis

United States
Athira Pharma
Alturas Analytics, Inc.; Labcorp Drug Development Inc

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Peloton Therapeutics, Inc., a subsidiary of Merck...

Active, not recruiting

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Kidney Cancer | Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | ccRCC | RCC

United States
National Cancer Institute (NCI)

Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditions

United States, Canada

Search clinical trials for: [11C]MK-6884

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations